

**DRAFT RESOLUTION OF
THE EXTRAORDINARY GENERAL SHAREHOLDERS MEETING
MED LIFE S.A.**

No. 2 / [16.11.2026] / [17.11.2026]

The extraordinary general shareholders meeting of MED LIFE S.A. (the "**Meeting**"), a joint stock company managed in a one tier system and functioning under the laws of Romania, having its headquarters in Romania, Bucharest, no. 365, Calea Grivitei, district 1, registered with the National Office of the Trade Registry associated with the Bucharest Tribunal, under no. J1996003709402, EUID:ROONRC.J1996003709402, sole registration code 8422035, having a share capital subscribed and paid of RON 132,870,492 (hereinafter the "**Company**"), legally and statutorily convened, on the grounds of art. 117 of the Companies Law no. 31/1990, republished, as further amended and supplemented, of Law no. 24/2017 on issuers of financial instruments and market operations, republished, as further amended and supplemented ("**Law 24/2017**") and regulations adopted for the application thereof, corroborated with art. 10 of the Company's Articles of Association, by publication of the convening notice in the Official Gazette of Romania, Part IV no. [●] and in the newspaper "Bursa", edition [●] of 14.10.2026, as well as by sending the convening notice to the Bucharest Stock Exchange and to the Financial Supervisory Authority in the current report no. 56 of 14.10.2026,

Legally and statutorily assembled on [16.11.2026] / [17.11.2026], at 10.30 hours, in the [first][second] convening at the headquarters of the Company located in Bucharest, no. 365, Calea Grivitei, CEx building, district 1, attended in person or by representation as well as by casting the votes through correspondence, by a number of [●] shareholders holding on the Reference Date **09.11.2026** a total number of [●] shares bearing voting rights, representing [●]% of the total voting rights and [●]% of the share capital of the Company on the Reference Date,

RESOLVES

1. [By unanimous votes validly cast by all shareholders attending in person, represented or casting votes by correspondence in the Meeting]/
[By a total number of [●] shares for which valid votes have been cast, representing [●]% of the Company's share capital and a total number of [●] votes cast validly, of which [●] votes were cast "for" representing [●]% of the total number of votes held in the Meeting by the shareholders attending in person, represented and who have casted votes by correspondence in the Meeting, [●] votes were cast "against" representing [●]% of the total number of votes held in the Meeting by the shareholders attending in person, represented and who have casted votes by correspondence in the Meeting and [●] votes casted "abstained"]

[approves] / [rejects]

Authorization of the Company's Board of Directors to increase the Company's share capital as follows:

- 1.1. Authorization of the Company's Board of Directors, for a period of 18 months from adoption of the EGMS resolution, to increase the Company's share capital by a maximum 20% of the subscribed share capital at the date of authorisation, by issuing new ordinary, nominative shares, issued in dematerialized form, pursuant to Article 220¹ para. (2) of Law no. 31/1990 and Article 86 para (2) of Law no. 24/2017, through one or more issuances. Hence, the Board of Directors is authorised to issue up to an aggregate maximum number of 106,200,000 newly issued shares for the purpose of financing the continued development of the MedLife Group. Therefore, if the share capital increase is carried out by the Board of Directors at the maximum authorized level, the share capital shall be increased from RON 132,870,492 to a maximum amount of 159,420,492 RON (authorized share capital).**
- 1.2. Amendment of the Company's Articles of Association by supplementing it with a new article positioned after Article 9.4 and numbered 9.5, which shall read as follows:**
"9.5 The Board of Directors is authorized, until 16.05.2028 (inclusive), to increase the Company's share capital by a maximum 20% of the subscribed share capital at the date of authorisation, through one or more issuances of new ordinary dematerialized shares against cash contributions. The total maximum number of shares that may be issued on the basis of the authorisation is 106,200,000 newly issued shares, and the share capital can be increased up to a maximum amount of 159,420,492 RON (authorized share capital)."
- 1.3. Authorization and delegation to the Board of Directors of all powers to decide upon, approve and implement any share capital increase carried out pursuant to item 1.1, including, but not limited to, the powers to:**
 - a) based on the market conditions, set the timing of any share capital increase, including relevant subscription and offering periods, as well as decide whether one or several share capital increases are carried out, within the limits of the authorization granted;**
 - b) decide on the share capital increase structure and details, such as terms and conditions, intended use of proceeds, the methods of implementation, and the relevant timelines and periods for carrying out the share capital increase, the number of shares to be issued, the issue price or the mechanism for determining such price, whether in connection with the**

exercise of the pre-emption rights, a placement to third parties or within a public offering, as the case may be, the possibility of trading pre-emption and allocation rights, as well as the structure and all other terms of such placement and/or public offering and any other matters related to the implementation of the share capital increase;

- c) determine the placement method of any shares unsubscribed as a result of the exercise of the pre-emption rights, including their offering through a public offering or private placement, as applicable, the terms and conditions of any such offering or placement (such as the subscription mechanism, and procedure) and the cancellation of any shares remaining unsubscribed, if applicable;
- d) prepare, approve, submit and publish the documentation required in connection with the share capital increase, including but not limited to any prospectus, information document, offering document or the presentation document prepared on the basis of the exemption from the obligation to draw up a prospectus provided under Article 1(4)(db) and Article 1(5)(ba) of Regulation (EU) 1129/2017;
- e) carry out all formalities necessary or advisable in connection with the approval, implementation, completion and registration of any share capital increase, including the preparation and signing of any documents, the filing and receipt of any deeds and information, the issuance of any statements and decisions, and representing the Company before any competent authorities, institutions, bodies and registries for the purpose of implementing the share capital increase, including but not limited to: the Trade Registry, the Financial Supervisory Authority, the Central Depository S.A., the Bucharest Stock Exchange S.A.;
- f) acknowledge and validate the results of the subscription and allocation of the newly issued shares;
- g) approve and confirm the final amounts of the increase of the Company's share capital, within the limits of the validly made subscriptions, and adopt all decisions necessary to give effect thereto;
- h) approve amendments and update the Company's Articles of Association as a result of the share capital increase;
- i) approve the relevant dates and timelines relating to any share capital increase, including the record date, ex-date, guaranteed participation date, payment date and any other relevant dates required under applicable law or market regulations.

2. [By unanimous votes validly cast by all shareholders attending in person, represented or casting votes by correspondence in the Meeting]/

[By a total number of [●] shares for which valid votes have been cast, representing [●]% of the Company's share capital and a total number of [●] votes cast validly, of which

[●] votes were cast "for" representing [●]% of the total number of votes held in the Meeting by the shareholders attending in person, represented and who have casted votes by correspondence in the Meeting, [●] votes were cast "against" representing [●]% of the total number of votes held in the Meeting by the shareholders attending in person, represented and who have casted votes by correspondence in the Meeting and [●] votes casted "abstained"]

[approves] / [rejects]

Empowerment of the Chairman of the Board of Directors to prepare and sign, in the name and on behalf of the Company, to carry out and to file any documents, and to give any statements required for the registration/filing with the Trade Registry Office of the EGMS resolutions, as well as to carry out any other formalities, such as publication formalities, including paying any fees, requesting and receiving any documents/deeds issued by the Trade Registry Office and/or by any other competent authority, and granting them the right to delegate to another person the mandate to carry out the aforementioned formalities.

The aforementioned resolutions have been prepared and signed in Bucharest, in [4] original copies, each comprising [4] pages, today [16.11.2026] / [17.11.2026].

Meeting Chairman

[●]

Meeting Secretary

[●]